Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Controlled Trial ◽

Optimal Combination ◽

Stage Iii ◽

Phase 2 ◽

Dosing Schedule ◽

Multicentre Phase ◽

Stage Iii Melanoma ◽

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00362-9 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1691-1699 ◽

Cited By ~ 191

Author(s):

Christoph Röllig ◽

Hubert Serve ◽

Andreas Hüttmann ◽

Richard Noppeney ◽

Carsten Müller-Tidow ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Standard Therapy ◽

Controlled Trial ◽

Phase 2 ◽

Newly Diagnosed ◽

Multicentre Phase ◽

Randomised Controlled ◽

Acute Myeloid

Calorie restriction improves lipid-related emerging cardiometabolic risk factors in healthy adults without obesity: Distinct influences of BMI and sex from CALERIE™ a multicentre, phase 2, randomised controlled trial

EClinicalMedicine ◽

10.1016/j.eclinm.2021.101261 ◽

2022 ◽

Vol 43 ◽

pp. 101261

Author(s):

Kim M. Huffman ◽

Daniel C. Parker ◽

Manjushri Bhapkar ◽

Susan B. Racette ◽

Corby K. Martin ◽

...

Keyword(s):

Risk Factors ◽

Calorie Restriction ◽

Cardiometabolic Risk ◽

Controlled Trial ◽

Healthy Adults ◽

Cardiometabolic Risk Factors ◽

Phase 2 ◽

Multicentre Phase ◽

2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30151-2 ◽

2019 ◽

Vol 7 (9) ◽

pp. 673-683 ◽

Cited By ~ 45

Author(s):

William E Kraus ◽

Manjushri Bhapkar ◽

Kim M Huffman ◽

Carl F Pieper ◽

Sai Krupa Das ◽

...

Keyword(s):

Calorie Restriction ◽

Cardiometabolic Risk ◽

Controlled Trial ◽

Phase 2 ◽

Multicentre Phase ◽

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30326-2 ◽

2019 ◽

Vol 20 (8) ◽

pp. 1148-1159 ◽

Cited By ~ 65

Author(s):

Sylvie Bonvalot ◽

Piotr L Rutkowski ◽

Juliette Thariat ◽

Sébastien Carrère ◽

Anne Ducassou ◽

...

Keyword(s):

Hafnium Oxide ◽

Controlled Trial ◽

Locally Advanced ◽

Phase 2 ◽

Advanced Soft Tissue Sarcoma ◽

Multicentre Phase ◽

Radiotherapy Alone ◽

Oxide Nanoparticle ◽

Calorie Restriction Improves Lipid-Related Emerging Cardiometabolic Risk Factors in Healthy Non-Obese Adults: Distinct Influences of BMI and Sex From CALERIE™ - A Multicentre, Phase 2, Randomised Controlled Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3924150 ◽

2021 ◽

Author(s):

Kim M. Huffman ◽

Daniel C. Parker ◽

Manjushri Bhapkar ◽

Susan B. Racette ◽

Corby K. Martin ◽

...

Keyword(s):

Risk Factors ◽

Calorie Restriction ◽

Cardiometabolic Risk ◽

Controlled Trial ◽

Cardiometabolic Risk Factors ◽

Phase 2 ◽

Obese Adults ◽

Multicentre Phase ◽

Faculty Opinions recommendation of The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955094.793462652 ◽

2012 ◽

Author(s):

Chim Lang

Keyword(s):

Heart Failure ◽

Controlled Trial ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

Faculty Opinions recommendation of Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726215272.793539632 ◽

2017 ◽

Author(s):

Patrick Nana-Sinkam

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Previously Treated ◽

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00160-0 ◽

2021 ◽

Author(s):

Sanjay Ramakrishnan ◽

Dan V Nicolau ◽

Beverly Langford ◽

Mahdi Mahdi ◽

Helen Jeffers ◽

...

Keyword(s):

Controlled Trial ◽

Phase 2 ◽

Open Label ◽

Inhaled Budesonide ◽

Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial

Journal of Emergency Medicine ◽

10.1016/j.jemermed.2021.04.002 ◽

2021 ◽

Vol 60 (5) ◽

pp. 695

Author(s):

Anne Kathryn Watson ◽

Zachary B. Lewis

Keyword(s):

Cardiac Arrest ◽

Ventricular Fibrillation ◽

Controlled Trial ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Randomised Controlled ◽

Hospital Cardiac Arrest

Faculty Opinions recommendation of Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726342846.793584738 ◽

2021 ◽

Author(s):

Heidi Jacobe

Keyword(s):

Systemic Sclerosis ◽

Controlled Trial ◽

Phase 2 ◽

Safety And Efficacy ◽